N6-Methyladenosine–Modified KREMEN2 Promotes Tumorigenesis and Malignant Progression of High-Grade Serous Ovarian Cancer
- 12 April 2024
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 104 (6) , 102059
Abstract
No abstract availableKeywords
Funding Information
- China Medical University
This publication has 41 references indexed in Scilit:
- FTO promotes innate immunity by controlling NOD1 expression via m6A-YTHDF2 manner in teleostiScience, 2022
- The IGF2BP family of RNA binding proteins links epitranscriptomics to cancerSeminars in Cancer Biology, 2022
- Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: Implications in lipid metabolic disordersGenes & Diseases, 2021
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionCancer Cell, 2020
- Ovarian cancer relapse: From the latest scientific evidence to the best practiceCritical Reviews in Oncology/Hematology, 2019
- Regulation of Gene Expression by N-methyladenosine in CancerTrends in Cell Biology, 2019
- DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone MetastasisTranslational Oncology, 2018
- Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cellsEuropean Journal of Cancer, 2016
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Archiv, 2012
- Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF‐κB and induction of apoptosisInternational Journal of Cancer, 2009